Cost-Effectiveness Analyses To Determine Payment On Horizon – Waldmann
This article was originally published in The Gray Sheet
Executive Summary
Cost-effectiveness analyses likely will be incorporated into Medicare payment decisions once CMS integrates a disease management model into its payment structure, according to Johnson & Johnson Federal Affairs & Reimbursement Director Daniel Waldmann
You may also be interested in...
CMS To Meet With NASPE/HRS, Manufacturers To Review ICD Decision Process
Guidant maintains that its MADIT-II trial ethically could not have been extended to provide more evidence of the long-term benefits of ICDs for the entire study population
HCFA Criteria For Medicare Coverage Likely To Rekindle Cost Debate
The Health Care Financing Administration's "notice of intent" on Medicare coverage criteria proposes to consider cost as a factor in the agency's decision-making, but leaves the extent to which it would be used largely undefined.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.